Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBIT (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed EBIT for 13 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 102.2% to -$4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.3 million, a 27.4% decrease, with the full-year FY2025 number at -$13.3 million, down 27.4% from a year prior.
  • EBIT was -$4.5 million for Q4 2025 at Ekso Bionics Holdings, down from -$1.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$1.4 million in Q3 2025 to a low of -$4.6 million in Q4 2021.
  • A 5-year average of -$3.4 million and a median of -$3.4 million in 2021 define the central range for EBIT.
  • Biggest YoY gain for EBIT was 46.87% in 2025; the steepest drop was 102.2% in 2025.
  • Ekso Bionics Holdings' EBIT stood at -$4.6 million in 2021, then increased by 2.55% to -$4.4 million in 2022, then increased by 22.25% to -$3.4 million in 2023, then surged by 35.34% to -$2.2 million in 2024, then tumbled by 102.2% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's EBIT are -$4.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$4.0 million (Q2 2025).